Navigation Links
FirstMark Welcomes Renowned Cardiologist and Researcher Dr. Prediman K. Shah to Scientific Advisory Board
Date:6/13/2012

SAN DIEGO, June 13, 2012 /PRNewswire-iReach/ -- FirstMark, the diagnostic division of GenWay Biotech, announced today that Dr. Prediman K. (PK) Shah has joined its Scientific Advisory Board.

Dr. Shah is Professor at Cedars-Sinai Professorial Series and Director of the Division of Cardiology. He also is the Director of the Oppenheimer Atherosclerosis Research Center at Cedars-Sinai Medical Center where he leads several studies that focus on heart disease prevention and treatment. Dr. Shah holds the Shapell and Webb Family Chair in Clinical Cardiology at Cedars-Sinai. Dr. Shah has been Professor of Medicine at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA) since 1992. Between 1992 and 2005, Dr. Shah and his colleagues conducted revolutionary research on mutant apo-A1 protein, called Apo-A1 Milano that produced a form of HDL that provided greater protection against atherosclerosis and vascular inflammation. In separate studies conducted, Dr. Shah found that a vaccine created from LDL significantly reduced plaque buildup in animals that had high cholesterol levels.

"We are very pleased Dr. Shah has joined FirstMark's advisory team," said Thomas Silberg, President and CEO of GenWay Biotech. "His outstanding background in cardiovascular medicine, focus on prevention, and extensive experience in research will be a critical support as we continue to build clinical interest and application for FirstMark PREvent."

Dr. Shah joins the FirstMark Scientific Advisory Board that is composed of innovative and nationally recognized leaders in cardiology and research. Each of these individuals has made substantial contributions to the field of cardiology. The main focus of the Board is to provide guidance for further clinical development and validation of FirstMark's new cardiovascular test PREvent. PREvent is the first and only multiple biomarker blood test on the market that predicts near term (2-3 years) risk of myocardial infarction in patients with suspected or confirmed, insignificant or significant coronary artery disease. The test was recently launched, and its remarkable data is receiving a strong reception throughout cardiovascular medicine.

The FirstMark Scientific Advisory Board is comprised of prominent cardiologist and research scientists including:

George A. Beller, MD, MACC
Cardiologist, University of Virginia Health System
Past President of the American College of Cardiology
Past President of the Association of University Cardiologists
Past President of the Association of Professors of Cardiology

Stephen Epstein, MD
Executive Director of the Cardiovascular Research Institute (CRI), MedStar Health Research Institute
Clinical Professor of Medicine at the Georgetown University School of Medicine
Former Chief of the Cardiology Branch of the NHLBI at the National Institutes of Health in Bethesda, MD

Arshed Quyyumi, MD, FACC, FRCP
Tenured Professor of Medicine, Division of Cardiology, Emory University School of Medicine,
Co-Director, Emory Clinical Cardiovascular Research Institute

Prediman K. Shah, MD, FACC, FACP, FCCP
Director, Division of Cardiology at Cedars-Sinai Medical Center
Director, Oppenheimer Atherosclerosis Research Center at Cedars-Sinai Medical Center
Shapell and Webb Family Chair in Clinical Cardiology
Professor, Cedars-Sinai Professorial Series

Sergey Sikora, PhD, MBA
Sr. Vice President,  FirstMark

Robert Wilensky, MD
Professor of Medicine at the Hospital of the University of Pennsylvania
Director, Interventional Cardiology Research

Peter Wilson, MD
Professor of Medicine, Emory Clinical Cardiovascular Research Institute
Professor of Public Health at the Rollins School of Public Health
Director of Epidemiology and Genomic Medicine, Atlanta VA Medical Center
Co-Developer and former Director of Laboratories at the Framingham Heart Study,
National Heart, Lung, and Blood Institute, Framingham, Mass

For more information about FirstMark PREvent and the Scientific Advisory Board, visit FirstMarkPREvent.com

FirstMark PREvent
The study revealed superior cardiac risk information by identifying the top 5% of CAD at the highest risk of MI with a hazard ratio of 5.5. The data showed an annual average of 18.2% of significant CAD patients with all three biomarkers elevated experienced a myocardial infarction or death, compared to only 2.45% of significant CAD patients with all biomarkers normal. The multiple biomarker model adds markedly to traditional risk-prediction by significantly improving C-statistics from 0.695 for base model to 0.750, distinguishing high risk from low risk subjects.

About FirstMark
FirstMark is a division of GenWay Biotech, Inc. The FirstMark division is focused on the development and commercialization of non-invasive diagnostic and health monitoring tests for unmet clinical needs. Headquarters are located in the heart of San Diego's biotech community in the Sorrento Valley/Mesa area.

Media Contact:

Deborah Moore GenWay Biotech, 858-458-0866, dmoore@genwaybio.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE GenWay Biotech
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. FirstMark Welcomes Renowned Cardiologist and Researcher Dr. Prediman K. Shah to Scientific Advisor Board
2. FirstMark Exhibiting at the Inaugural Atlanta Clinical Cardiology Update
3. FirstMark Announces New Hire Jay Houtman as Southeast Regional Sales Manager
4. EMBO welcomes 55 leading life scientists as members
5. Renowned geneticist R. Rodney Howell receives ACMG Foundation Lifetime Achievement Award
6. UTMB researchers create powerful new method to analyze genetic data
7. Researchers at GW receive federal funds to study the effect earthquakes have on nuclear reactors
8. Stanford researchers help predict the oceans of the future with a mini-lab
9. Researchers complete the first epigenome in Europe
10. UC Santa Barbara researchers develop synthetic platelets
11. Researchers say tart cherries have the highest anti-inflammatory content of any food
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2016)... ANGELES , June 22, 2016 /PRNewswire/ ... identity management and verification solutions, has partnered ... edge software solutions for Visitor Management, Self-Service ... provides products that add functional enhancements ... partnership provides corporations and venues with an ...
(Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
(Date:6/7/2016)...  Syngrafii Inc. and San Antonio Credit Union ... integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution into ... result in greater convenience for SACU members and ... existing document workflow and compliance requirements. ... Highlights: ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... , ... June 24, 2016 , ... While the majority ... as the Cary 5000 and the 6000i models are higher end machines that use ... height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... MA (PRWEB) , ... June 23, 2016 , ... ... Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute ... platform of microbial tests introduced last year,” stated Bob Salter, Vice President of ...
Breaking Biology Technology: